Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6541449 | 1.00 | CXCR4 (0.55) | CXCR4OPRD1OPRL1DPP7CCR2 | |
| SCHEMBL7552049 | 0.95 | CXCR4 (0.56) | CXCR4OPRL1CCR2 | |
| SCHEMBL7454601 | 0.87 | OPRD1 (0.52) | OPRD1CCR2 | |
| SCHEMBL11419710 | 0.82 | KDM4E (0.59) | CXCR4 | |
| SCHEMBL11462791 | 0.82 | CCR2 (0.49) | CCR2 | |
| SCHEMBL4967411 | 0.81 | HTR5A (0.50) | DPP7 | |
| SCHEMBL13220242 | 0.81 | DPP7 (0.50) | CXCR4DPP7HTT | |
| SCHEMBL27492 | 0.80 | — | — | |
| SCHEMBL5967967 | 0.80 | OPRD1 (0.53) | OPRD1 | |
| SCHEMBL24447814 | 0.78 | MAPK1 (0.59) | OPRD1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-04 | — | — | US | disclosed |
| US-6787543-B2 | PREPARATION OF TACHYKININ ANTAGONISTS; SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20030176430-A1 | Benzhydryl derivatives | ASTELLAS PHARMA INC. (JP) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176430-A1 | Benzhydryl derivatives | BDKRB1, BDKRB2, TACR1 | CXCR4 998/4885OPRD1 77/4885OPRL1 83/4885 |
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | BDKRB1, BDKRB2, TACR1 | CXCR4 1052/4885OPRD1 135/4885OPRL1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.